Nasopharyngeal carcinoma
Item
1. histologically proven npc.
boolean
C2931822 (UMLS CUI [1])
Nasopharyngeal carcinoma | TNM clinical staging
Item
2. any clinical stage npc as defined by the ajcc/uicc system.
boolean
C2931822 (UMLS CUI [1])
C3258246 (UMLS CUI [2])
Therapeutic radiology procedure | Chemoradiotherapy | Immunotherapy | Investigational New Drugs
Item
3. no prior radiotherapy, chemoradiotherapy, immunotherapy or investigational agents.
boolean
C1522449 (UMLS CUI [1])
C0436307 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
Anti-Inflammatory Agents, Non-Steroidal | Adrenal Cortex Hormones
Item
4. no prior nsaids or corticosteroids for at least 4 weeks.
boolean
C0003211 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
ECOG performance status
Item
5. ecog performance status ≤ 2.
boolean
C1520224 (UMLS CUI [1])
organ function
Item
6. adequate end organ function
boolean
C0678852 (UMLS CUI [1])
Life Expectancy
Item
7. life expectancy > 3 months.
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
8. signed informed consent -
boolean
C0021430 (UMLS CUI [1])
celecoxib Take Unable | gefitinib Take Unable
Item
1. inability to take celecoxib and gefitinib for the specified period of time (14 days) prior to definitive therapy.
boolean
C0538927 (UMLS CUI [1,1])
C1290952 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C1122962 (UMLS CUI [2,1])
C1290952 (UMLS CUI [2,2])
C1299582 (UMLS CUI [2,3])
Neoplasm Visible | Nasopharyngoscopy | Biopsy
Item
2. tumor not visible on fibre nasopharyngoscopy for biopsy.
boolean
C0027651 (UMLS CUI [1,1])
C0205379 (UMLS CUI [1,2])
C0189025 (UMLS CUI [2])
C0005558 (UMLS CUI [3])
Peptic Ulcer
Item
3. known peptic ulcer disease.
boolean
C0030920 (UMLS CUI [1])
Interstitial Lung Disease Evidence of
Item
4. evidence of clinically active interstitial lung disease.
boolean
C0206062 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Malignant Neoplasms | Carcinoma in situ of uterine cervix Treated | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated
Item
5. previous or concomitant malignancies with the exception of adequately treated carcinoma-in-situ of the cervix and basal or squamous cell carcinoma of the skin.
boolean
C0006826 (UMLS CUI [1])
C0851140 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C0007117 (UMLS CUI [3,1])
C1522326 (UMLS CUI [3,2])
C0553723 (UMLS CUI [4,1])
C1522326 (UMLS CUI [4,2])
Pregnancy | Breast Feeding | Childbearing Potential Serum pregnancy test negative
Item
6. women who are pregnant or lactating. females with child-bearing potential must have a negative serum pregnancy test within 7 days prior to study enrolment.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0430061 (UMLS CUI [3,2])
Childbearing Potential Contraceptive methods Lacking
Item
7. women of childbearing potential who are not practising adequate contraception.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
Comorbidity Compliance behavior Limited
Item
8. concurrent medical problems that would significantly limit compliance with the study.
boolean
C0009488 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
Medical condition Resulting in Study Subject Participation Status Inappropriate | Respiration Disorder Unstable | Respiration Disorder Uncompensated | Heart Disease Unstable | Heart Disease Uncompensated | Kidney Disease Unstable | Kidney Disease Uncompensated | Liver disease Unstable | Liver disease Uncompensated
Item
9. presence of any underlying medical conditions (eg. unstable or uncompensated respiratory, cardiac, renal or hepatic disease) that in the opinion of the investigator would make the patient unsuitable for study participation.
boolean
C3843040 (UMLS CUI [1,1])
C0332294 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C1548788 (UMLS CUI [1,4])
C0035204 (UMLS CUI [2,1])
C0443343 (UMLS CUI [2,2])
C0035204 (UMLS CUI [3,1])
C0205433 (UMLS CUI [3,2])
C0018799 (UMLS CUI [4,1])
C0443343 (UMLS CUI [4,2])
C0018799 (UMLS CUI [5,1])
C0205433 (UMLS CUI [5,2])
C0022658 (UMLS CUI [6,1])
C0443343 (UMLS CUI [6,2])
C0022658 (UMLS CUI [7,1])
C0205433 (UMLS CUI [7,2])
C0023895 (UMLS CUI [8,1])
C0443343 (UMLS CUI [8,2])
C0023895 (UMLS CUI [9,1])
C0205433 (UMLS CUI [9,2])
Hypersensitivity celecoxib | Hypersensitivity gefitinib | Hypersensitivity celecoxib Excipient | Hypersensitivity gefitinib Excipient | Allergy to sulfonamides | Allergic Reaction NSAIDS Ingestion
Item
10. known hypersensitivity to celecoxib and gefitinib or any of the excipients of the products, known sulphonamide sensitivity and allergic reaction following the ingestion of nsaids.
boolean
C0020517 (UMLS CUI [1,1])
C0538927 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1122962 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0538927 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C1122962 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0038757 (UMLS CUI [5])
C1527304 (UMLS CUI [6,1])
C0003211 (UMLS CUI [6,2])
C0232478 (UMLS CUI [6,3])
HIV Infections | Hepatitis B | Hepatitis C
Item
11. known hiv, hbv or hcv infection. -
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])